Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. [electronic resource]
Producer: 20110801Description: 236-42 p. digitalISSN:- 1421-9832
- Adalimumab
- Anti-Inflammatory Agents -- economics
- Antibodies, Monoclonal -- economics
- Antibodies, Monoclonal, Humanized
- Cost-Benefit Analysis
- Etanercept
- Germany
- Health Care Costs
- Humans
- Immunoglobulin G -- economics
- Immunologic Factors -- economics
- Infliximab
- Psoriasis -- drug therapy
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Remission Induction
- Ustekinumab
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.